1. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
- Author
-
Michael E. Goldberg, Phillip J. Stephens, Aju Mathew, Peter C. Lucas, John Cho, Siraj M. Ali, Ryan J. Hartmaier, Margaret Rosenzweig, Jennifer M. Atkinson, Rena D. Callahan, C Williams, P. Vanden Borre, Ben Ho Park, Z. Erdogan-Yildirim, J.S. Ross, Brandon Young, G.M. Frampton, M. Tsai, Adam Brufsky, Adrian V. Lee, Jon Chung, Juliann Chmielecki, Shannon Puhalla, Rebecca J. Watters, Christine A. Parachoniak, L. Cao, Sally E. Trabucco, James Suh, Samantha Morley, N. E. Davidson, Nolan Priedigkeit, Julio Peguero, I. Sachelarie, Amir Bahreini, Steffi Oesterreich, Barbara Haley, Alison M. Nagle, and Brian Leyland-Jones
- Subjects
0301 basic medicine ,Antineoplastic Agents, Hormonal ,Recombinant Fusion Proteins ,Breast Neoplasms ,Drug resistance ,Fusion gene ,03 medical and health sciences ,breast cancer ,0302 clinical medicine ,Breast cancer ,Breast Tumors ,medicine ,Humans ,Missense mutation ,Breast ,Neoplasm Metastasis ,business.industry ,ESR1 fusion ,endocrine therapy resistance ,Editorials ,structural variation ,Estrogen Receptor alpha ,High-Throughput Nucleotide Sequencing ,Cancer ,Original Articles ,Hematology ,medicine.disease ,Fusion protein ,Metastatic breast cancer ,3. Good health ,body regions ,Gene expression profiling ,Editor's Choice ,Tamoxifen ,030104 developmental biology ,Oncology ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,Female ,genomic profiling ,business - Abstract
Background Estrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated with endocrine-therapy resistance, recurrent ESR1 fusion proteins have yet to be identified in advanced breast cancer. Patients and methods To identify genomic structural rearrangements (REs) including gene fusions in acquired resistance, we undertook a multimodal sequencing effort in three breast cancer patient cohorts: (i) mate-pair and/or RNAseq in 6 patient-matched primary-metastatic tumors and 51 metastases, (ii) high coverage (>500×) comprehensive genomic profiling of 287–395 cancer-related genes across 9542 solid tumors (5216 from metastatic disease), and (iii) ultra-high coverage (>5000×) genomic profiling of 62 cancer-related genes in 254 ctDNA samples. In addition to traditional gene fusion detection methods (i.e. discordant reads, split reads), ESR1 REs were detected from targeted sequencing data by applying a novel algorithm (copyshift) that identifies major copy number shifts at rearrangement hotspots. Results We identify 88 ESR1 REs across 83 unique patients with direct confirmation of 9 ESR1 fusion proteins (including 2 via immunoblot). ESR1 REs are highly enriched in ER-positive, metastatic disease and co-occur with known ESR1 missense alterations, suggestive of polyclonal resistance. Importantly, all fusions result from a breakpoint in or near ESR1 intron 6 and therefore lack an intact ligand binding domain (LBD). In vitro characterization of three fusions reveals ligand-independence and hyperactivity dependent upon the 3′ partner gene. Our lower-bound estimate of ESR1 fusions is at least 1% of metastatic solid breast cancers, the prevalence in ctDNA is at least 10× enriched. We postulate this enrichment may represent secondary resistance to more aggressive endocrine therapies applied to patients with ESR1 LBD missense alterations. Conclusions Collectively, these data indicate that N-terminal ESR1 fusions involving exons 6–7 are a recurrent driver of endocrine therapy resistance and are impervious to ER-targeted therapies.
- Published
- 2018
- Full Text
- View/download PDF